INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
npj Vaccines
October 2021
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
Nature Communications
May 2020
The Lancet Infectious Diseases
July 2019
Filter by Category
Title | Disease Target | Product |
---|---|---|
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Molecular Therapy — November 2017 |
Disease TargethTERT | ProductINO-5401 |
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity
Cancer Immunology Research — September 2013 |
Disease TargethTERT | ProductINO-5401 |
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Molecular Therapy — February 2017 |
Disease TargetWT1 | ProductINO-5401 |
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Molecular Therapy — March 2020 |
Disease TargetPSA | ProductINO-5151 |
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
Human Vaccines — January 2011 |
Disease TargetPSA, PSMA | ProductINO-5401 |
Title | Disease Target | Product |
---|---|---|
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
JCI Insight — April 2019 |
Disease TargetHER2 |
Title | Disease Target | Product |
---|---|---|
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle
Vaccine — September 2011 |
Disease TargetDelivery | ProductCELLECTRA |
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses
Vaccine — June 2019 |
Disease TargetDelivery | ProductCELLECTRA |
Title | Disease Target | Product |
---|---|---|
Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020 |
Disease TargetCOVID-19 | ProductINO-4800 |
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases — December 2021 |
Disease TargetCOVID-19 | ProductINO-4800 |
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases — January 2022 |
Disease TargetCOVID-19 | ProductINO-4800 |
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
npj Vaccines — October 2021 |
Disease TargetCOVID-19 | ProductINO-4800 |
© Copyright 2023 INOVIO Pharmaceuticals. All rights reserved.